Prescribing trends of inhaler treatments for asthma and chronic obstructive pulmonary disease within a resource-constrained environment in the Scottish national health service: findings and implications

References

• Papi A, Brightling C, Pedersen SE, et al. Asthma. Lancet. 2018;391(10122):783–800.
   PubMed Web of Science ®Google Scholar
• Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2163–2196.
   PubMed Web of Science ®Google Scholar
• Asthma UK. Asthma facts and statistics. 2017. [cited 2019 Mar 20]. Available from: https://www.asthma.org.uk/about/media/facts-and-statistics/
   Google Scholar
• Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14–23.
   PubMed Web of Science ®Google Scholar
• British Lung Foundation. Chronic obstructive pulmonary disease (COPD). statistics; 2017. Available from: https://statistics.blf.org.uk/copd
   Google Scholar
• Burney PG, Patel J, Newson R, et al. Global and regional trends in COPD mortality, 1990-2010. Eur Respir J. 2015;45(5):1239–1247.
   PubMed Web of Science ®Google Scholar
• Ntritsos G, Franek J, Belbasis L, et al. Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:1507–1514.
   PubMed Web of Science ®Google Scholar
• Healthier Scotland - Scottish Government – COPD best practice guide. [cited 2019 Mar 20]. Available from: file:///C:/Users/mail/Downloads/00527135.pdf.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. POCKET GUIDE TO COPD DIAGNOSIS, MANAGEMENT, AND PREVENTION. A guide for health care professionals. 2017. [cited 2019 Mar 19]. Available from: https://goldcopd.org/wp-content/uploads/2016/12/wms-GOLD-2017-Pocket-Guide.pdf.
   Google Scholar
• Miravitlles M, Vogelmeier C, Roche N, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016;47(2):625–637.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2018. [cited 2019 Mar 21]. Available from: file:///C:/Users/mail/Downloads/wms-GINA-2018-report-V1.3-002.pdf.
   Google Scholar
• NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Guideline chronic obstructive pulmonary disease in over 16s: diagnosis and management. Draft for consultation, July 2018. [cited 2019 Mar 23]. Available from: https://www.nice.org.uk/guidance/gid-ng10026/documents/short-version-of-draft-guideline
   Google Scholar
• NICE Guideline NG80. Asthma: diagnosis, monitoring and chronic asthma management. November 2017. [cited 2019 Mar 20]. Available from: https://www.nice.org.uk/guidance/ng80.
   Google Scholar
• Campbell SM, Reeves D, Kontopantelis E, et al. Effects of pay for performance on the quality of primary care in England. N Engl J Med. 2009;361(4):368–378.
   PubMed Web of Science ®Google Scholar
• NICE quality and outcomes framework indicator – asthma and chronic obstructive pulmonary disease. [cited 2019 Mar 29]. Available from: https://www.nice.org.uk/standards-and-indicators/qofindicators.
   Google Scholar
• SIGN 153. British guideline on the management of asthma. September 2016. [cited 2019 Mar 18]. Available from: https://www.sign.ac.uk/assets/sign153.pdf
   Google Scholar
• NHS Quality Improvement Scotland. Clinical Standards. March 2010. Chronic obstructive pulmonary disease services. [cited 2019 Mar 18]. Available from: file:///C:/Users/mail/Downloads/COPD_STANF_MAR10.pdf.
   Google Scholar
• NHS Scotland, The Scottish Government. Respiratory prescribing strategy 2014 to 2016. June 2014. [cited 2019 Mar 20]. Available from: https://www.sehd.scot.nhs.uk/cmo/CMO(2014)14-Respiratory%20Prescribing%20Strategy%20June%202014.pdf.
   Google Scholar
• Principles of Prescribing in Adult Asthma 2018 March. [cited 2019 Mar 20]. Available from: http://foi.nhsgrampian.org/globalassets/foidocument/foi-public-documents1—all-documents/nhsgmcn_asthma.pdf.
   Google Scholar
• NHS Grampian respiratory MCN – principles of prescribing inhaled therapies in COPD. March 2018. [cited 2019 Mar 21]. Available from: file:///C:/Users/mail/Desktop/My%20documents/Ongoing%20papers/Scotland%20Respiratory/nhsgmcn_copd.pdf.
   Google Scholar
• GOLD. Teaching slide set. 2018. [cited 2019 Mar 21]. Available from: https://goldcopd.org/gold-teaching-slide-set/.
   Google Scholar
• Tricco AC, Strifler L, Veroniki AA, et al. Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis. BMJ Open. 2015;5(10):e009183.
   PubMed Web of Science ®Google Scholar
• Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2010(5):Cd007891.
   Google Scholar
• Nannini L, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007(4):Cd003794.
   Google Scholar
• Puhan MA, Bachmann LM, Kleijnen J, et al. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med. 2009;7:2.
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449–456.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789.
   PubMed Web of Science ®Google Scholar
• Chan R, Sousa AR, Hynds P, et al. Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler versus a multi-dose inhaler in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2017;43:12–19.
   PubMed Web of Science ®Google Scholar
• Jones R, Martin J, Thomas V, et al. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study. Int J Chron Obstruct Pulmon Dis. 2017;12:2445–2454.
   PubMed Web of Science ®Google Scholar
• Yatera KYK, Nishida C, Noguchi S, et al. Real-world effects of two inhaled corticosteroid/long-acting b2-agonist combinations in the treatment of asthma. J Asthma. 2014;51(7):762–768.
   PubMed Web of Science ®Google Scholar
• Altaf M, Zubedi AM, Nazneen F, et al. Cost-effectiveness analysis of three different combinations of inhalers for severe and very severe chronic obstructive pulmonary disease patients at a tertiary care teaching hospital of South India. Perspect Clin Res. 2015;6(3):150–158.
   PubMedGoogle Scholar
• Kern DM, Davis J, Williams SA, et al. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study. Respir Res. 2015;16:52.
   PubMed Web of Science ®Google Scholar
• Roman-Rodriguez M, Metting E, Gacia-Pardo M, et al. Wrong inhalation technique is associated to poor asthma clinical outcomes. Is there room for improvement? Curr Opin Pulm Med. 2019;25(1):18–26.
   PubMed Web of Science ®Google Scholar
• Chrystyn H, van der Palen J, Sharma R, et al. Device errors in asthma and COPD: systematic literature review and meta-analysis. NPJ Prim Care Respir Med. 2017;27(1):22.
   PubMed Web of Science ®Google Scholar
• Ozturk C, Aldag Y, Yilmaz Demirci N. Evaluation and importance of different types of inhaler device in patients with chronic obstructive lung disease. Tuberk Toraks. 2017;65(2):69–79.
   PubMed Web of Science ®Google Scholar
• Virchow JC, Crompton GK, Dal Negro R, et al. Importance of inhaler devices in the management of airway disease. Respir Med. 2008;102(1):10–19.
   PubMed Web of Science ®Google Scholar
• Sanchis J, Gich I, Pedersen S. Systematic review of errors in inhaler use: has patient technique improved over time? Chest. 2016;150(2):394–406.
   PubMed Web of Science ®Google Scholar
• Lewis A, Torvinen S, Dekhuijzen PN, et al. The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries. BMC Health Serv Res. 2016;16:251.
   PubMed Web of Science ®Google Scholar
• NHS Lothian. Lothian prescribing bulletin issue No. 79 May 2016. Formulary changes to improve care: asthma and COPD. [cited 2019 Mar 18]. Available from: http://www.ljf.scot.nhs.uk/PrescribingBulletins/Prescribing%20Bulletins/Lothian%20Prescribing%20Bulletin%20Issue%2079%20May%202016%20v2%20resp%20amend.pdf
   Google Scholar
• NHS greater glasgow and clyde. Clinical guideline. Asthma preferred list inhaler device guide (Primary and Secondary care). 2016 [cited 2017 Nov]. Available from: http://www.nhsggc.org.uk/media/245912/asthma-inhaler-device-preferred-list.pdf
   Google Scholar
• NHS greater glasgow and clyde. Greater glasgow and clyde medicines. Medicines update asthma/COPD inhalers of choice. 2018. [cited 2019 Mar 20]. Available from: http://www.ggcprescribing.org.uk/blog/asthma-copd-inhalers-choice/
   Google Scholar
• Leporowski A, Godman B, Kurdi A, et al. Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national health service: influence and implications. Expert Rev Pharmacoecon Outcomes Res. 2018;18(6):655–666.
   PubMed Web of Science ®Google Scholar
• Godman B, Bishop I, Finlayson AE, et al. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharmacoecon Outcomes Res. 2013;13(4):469–482.
   PubMed Web of Science ®Google Scholar
• Godman B, Kurdi A, McCabe H, et al. Ongoing activities to influence the prescribing of proton pump inhibitors within the Scottish National Health Service: their effect and implications. GaBI J. 2018;7(4):142–151.
   Google Scholar
• Haughney J, Price D, Barnes NC, et al. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med. 2010;104(9):1237–1245.
   PubMed Web of Science ®Google Scholar
• Klijn SL, Hiligsmann M, Evers S, et al. Effectiveness and success factors of educational inhaler technique interventions in asthma & COPD patients: a systematic review. NPJ Prim Care Respir Med. 2017;27(1):24.
   PubMed Web of Science ®Google Scholar
• Normansell R, Kew KM, Mathioudakis AG. Interventions to improve inhaler technique for people with asthma. Cochrane Database Syst Rev. 2017;3:Cd012286.
   PubMed Web of Science ®Google Scholar
• Lopez-Vina A, Giner J, Molina J, et al. Multidisciplinary consensus on the nonadherence to clinical management of inhaled therapy in Spanish asthma patients. Clin Ther. 2017;39(8):1730–45.e1.
   PubMed Web of Science ®Google Scholar
• Price D, Keininger DL, Viswanad B, et al. Factors associated with appropriate inhaler use in patients with COPD – lessons from the REAL survey. Int J Chron Obstruct Pulmon Dis. 2018;13:695–702.
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Povero M. The economic impact of educational training assessed by the handling questionnaire with three inhalation devices in asthma and chronic obstructive pulmonary disease patients. Clinicon Econ Outcomes Res. 2016;8:171–176.
   PubMed Web of Science ®Google Scholar
• Bjornsdottir US, Gizurarson S, Sabale U. Potential negative consequences of non-consented switch of inhaled medications and devices in asthma patients. Int J Clin Pract. 2013;67(9):904–910.
   PubMed Web of Science ®Google Scholar
• Lavorini F, Ninane V, Haughney J. Switching from branded to generic inhaled medications: potential impact on asthma and COPD. Expert Opin Drug Deliv. 2013;10(12):1597–1602.
   PubMed Web of Science ®Google Scholar
• Godman B, Kurdi A, McCabe H, et al. Ongoing initiatives within the Scottish national health service to affect the prescribing of SSRIs and their influence. J Comp Eff Res. 2019;8(7):535-547.
   Google Scholar
• Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert review of pharmacoeconomics & outcomes research. 2012;12(1):125-30
   Google Scholar
• Community dispensing: prescription cost analysis 2018 July. [cited 2019 Mar 18]. Available from: http://isdscotland.org/Health-Topics/Prescribing-and-Medicines/Community-Dispensing/Prescription-Cost-Analysis/.
   Google Scholar
• BNF. Authoritative and practical. 2018. [cited 2019 Mar 18]. Available from: https://www.bnf.org/
   Google Scholar
• NHS Scotland. National therapeutic indicators. 2012 – baseline data. [cited 2019 Mar 20]. Available from: http://www.sehd.scot.nhs.uk/pca/PCA2012(M)08report.pdf.
   Google Scholar
• WHO. WHO collaborating centre for drug statistics methodology. ATC/DDD Index. [cited 2019 Mar 6]. Available from: https://www.whocc.no/[
   Google Scholar
• NHS Scotland. The Scottish Government. National therapeutic indicators 2013 – baseline report. [cited 2019 Mar 10]. Available from: file:///C:/Users/mail/Desktop/My%20documents/Ongoing%20papers/Scotland%20PPIs/National%20Therapeutic%20Indicators%20Scotland%202013.pdf.
   Google Scholar
• Wettermark B, Godman B, Jacobsson B, et al. Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences. Applied health economics and health policy. Appl Health Econ Health Policy. 2009;7(3):137–147.
   PubMedGoogle Scholar
• Godman B, Shrank W, Andersen M, et al. Policies to enhance prescribing efficiency in europe: findings and future implications. Frontiers in pharmacology. 2010;1:141.
   PubMed Web of Science ®Google Scholar
• Godman B, Shrank W, Andersen M, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res. 2010;10(6):707–722.
   PubMed Web of Science ®Google Scholar
• Moon JC, Godman B, Petzold M, et al. Different initiatives across Europe to enhance losartan utilization post generics: impact and implications. Front Pharmacol. 2014;5:219.
   PubMed Web of Science ®Google Scholar
• Garuoliene K, Godman B, Gulbinovic J, et al. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res. 2011;11(3):343–349.
   PubMed Web of Science ®Google Scholar
• Godman B, Burkhardt T, Bucsics A, et al. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future. Expert Rev Pharmacoecon Outcomes Res. 2009;9(5):475–484.
   PubMedGoogle Scholar
• Godman B, Wettermark B, Hoffmann M, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res. 2009;9(1):65–83.
   PubMedGoogle Scholar
• Martikainen JE, Saastamoinen LK, Korhonen MJ, et al. Impact of restricted reimbursement on the use of statins in Finland: a register-based study. Med Care. 2010;48(9):761–766.
   PubMed Web of Science ®Google Scholar
• Audit Scotland. Prescribing in general practice in Scotland. 2013. [cited 2019 Mar 10]. Available from: file:///C:/Users/mail/Desktop/My%20documents/Strathclyde/Alec%20and%20high%20price%20medicines/Lipid%20lowering%20paper/Audit%20Scotland%202013.pdf.
   Google Scholar
• Audit Scotland. Supporting prescribing in general practice – a progress report. 2003 June. [cited 2019 Mar 12]. Available from: http://www.audit-scotland.gov.uk/docs/health/2003/nr_030626_supporting_prescribing_km.pdf.
   Google Scholar
• NHS Scotland. National therapeutic indicators 2014/2015. [cited 2019 Mar 18]. Available from: http://www.sehd.scot.nhs.uk/publications/DC20141201nti.pdf
   Google Scholar
• NHS Scotland. National therapeutic indicators 2015/2016. [cited 2019 Mar 18]. Available from: file:///C:/Users/mail/Desktop/My%20documents/Ongoing%20papers/Scotland%20PPIs/Therapeutic%20indicators%202015%20to%202016.pdf.
   Google Scholar
• NHS Scotland Greater Glasgow and Clyde. National therapeutic indicators 2017-18. [cited 2019 Mar 10]. Available from: http://www.ggcmedicines.org.uk/media/uploads/ps_primary_care/mupc__april_2017.pdf
   Google Scholar
• NHS Scotland Greater Glasgow and Clyde. Respiratory inhalers identification guide. 2013 September. [cited 2019 Mar 12]. Available from: http://www.ggcprescribing.org.uk/media/uploads/prescribing_resources/inhaler_indentification_guide_-_1310.pdf.
   Google Scholar
• Audit Scotland. NHS in Scotland 2016. [cited 2019 Mar 12]. Available from: http://www.audit-scotland.gov.uk/uploads/docs/report/2016/nr_161027_nhs_overview.pdf.
   Google Scholar
• The Scottish Government. Improving health & wellbeing of people with long term conditions in Scotland: a national action plan. 2009 June. [cited 2019 Mar 10]. Available from: https://www.sehd.scot.nhs.uk/mels/CEL2009_23.pdf.
   Google Scholar
• NHS Lothian. Lothian chronic obstructive pulmonary disease (COPD) guidelines. 2010 March. [cited 2019 Mar 18]. Available from: http://www.lothianrespiratorymcn.scot.nhs.uk/wp-content/uploads/2009/05/Lothian-COPD-Guidelines2.pdf.
   Google Scholar
• NHS Lothian respiratory managed clinical network 2014 to 2015. [cited 2019 Mar 12]. Available from: http://www.lothianrespiratorymcn.scot.nhs.uk/.
   Google Scholar
• NHS Tayside. Chronic obstructive pulmonary disease (COPD) guidelines. 2014. [cited 2019 Mar 18]. Availabel from: https://www.nhstaysideadtc.scot.nhs.uk/TAPG%20html/Section%203/PDF%20docs/COPD%20guidelines.pdf.
   Google Scholar
• NHS GGC Primary Care COPD guideline. [cited 2013 September]. Available from: http://library.nhsggc.org.uk/media/223647/COPD%20guidelines.pdf.
   Google Scholar
• Asthma UK. UK Inhaler Group’s joint statement on Duaklir® (aclidinium/formoterol fumarate) Genuair® packaging change. [cited 2019 Mar 25]. Available from: https://www.asthma.org.uk/about/media/news/uk-inhaler-groups-joint-statement-on-duaklir-aclidinium–formoterol-fumarate-genuair-packaging-change/.
   Google Scholar
• Lavorini F, Braido F, Baiardini I, et al. Asthma and COPD: interchangeable use of inhalers. A document of Italian Society of Allergy, Asthma and Clinical Immmunology (SIAAIC) & Italian Society of Respiratory Medicine (SIMeR). Pulm Pharmacol Ther. 2015;34:25–30.
   PubMed Web of Science ®Google Scholar
• Bell C, Coutinho A, Farr E. Clinical and economic outcomes associated with the use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium bromide 18 mcg as initial maintenance treatment for chronic obstructive pulmonary disease in managed care. J Med Econ. 2018;21(6):8–629.
   Web of Science ®Google Scholar